Skip to main content
. Author manuscript; available in PMC: 2021 Dec 15.
Published in final edited form as: Virology. 2021 May 10;560:17–33. doi: 10.1016/j.virol.2021.04.013

Fig 4. Inhibition of various mechanisms of ZIKV infection by sTIM1dMLDR801.

Fig 4.

Fig 4.

Fig 4.

Fig 4.

The results shown are averages and standard deviations of the triplicate experiment. A) HMVEC were infected with ZIKV replicon with or without Gas6 (1 μg/ml) and NC dMLD R801 (30 μg/ml). B) ZIKV replicon was incubated with various concentrations of ZKA64 or sTIM1dMLD R801, and HMVEC were infected with the incubated virus in the presence of Gas6 (1 μg/ml). C) ZIKV replicon was incubated with 1 or 10 μg/ml of ZKA64 or sTIM1dMLDR801, or control medium. 293T, TIM-4 293T, DC-SIGN 293T, or CD300A 293T cells were infected with the incubated virus for 2 hours, and infections were analyzed by flow cytometry 24 hours post-infection. The MOI used for the experiments shown in Fig 4B and C are 0.02 and 0.03, respectively. Significance was calculated by comparing TIM-4, CD300A, or DC-SIGN 293T cell infection without blocking reagents to those with blocking reagents, using a two-sample two-sided unpaired student t-test (**, p<0.01).